Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. more
Time Frame | TVTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2% | -0.94% | -2.6% |
1-Month Return | -5.67% | -5.08% | -1.08% |
3-Month Return | 18.19% | -10.62% | 3.45% |
6-Month Return | 120.15% | -6.18% | 8.57% |
1-Year Return | 81.87% | 1.98% | 24.3% |
3-Year Return | -44.98% | -0.93% | 25.58% |
5-Year Return | 14.64% | 33.84% | 84.07% |
10-Year Return | 34.72% | 102.52% | 185.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 175.34M | 198.32M | 227.49M | 212.02M | 145.24M | [{"date":"2019-12-31","value":77.08,"profit":true},{"date":"2020-12-31","value":87.18,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.2,"profit":true},{"date":"2023-12-31","value":63.84,"profit":true}] |
Cost of Revenue | 5.23M | 6.13M | 6.78M | 7.59M | 11.45M | [{"date":"2019-12-31","value":45.71,"profit":true},{"date":"2020-12-31","value":53.5,"profit":true},{"date":"2021-12-31","value":59.25,"profit":true},{"date":"2022-12-31","value":66.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 170.10M | 192.19M | 220.71M | 204.43M | 133.79M | [{"date":"2019-12-31","value":77.07,"profit":true},{"date":"2020-12-31","value":87.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":92.62,"profit":true},{"date":"2023-12-31","value":60.62,"profit":true}] |
Gross Margin | 97.01% | 96.91% | 97.02% | 96.42% | 92.12% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":99.89,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.38,"profit":true},{"date":"2023-12-31","value":94.95,"profit":true}] |
Operating Expenses | 269.91M | 267.57M | 360.21M | 455.99M | 521.93M | [{"date":"2019-12-31","value":51.71,"profit":true},{"date":"2020-12-31","value":51.27,"profit":true},{"date":"2021-12-31","value":69.02,"profit":true},{"date":"2022-12-31","value":87.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (99.81M) | (75.38M) | (139.50M) | (251.56M) | (376.74M) | [{"date":"2019-12-31","value":-9981000000,"profit":false},{"date":"2020-12-31","value":-7537700000,"profit":false},{"date":"2021-12-31","value":-13950500000,"profit":false},{"date":"2022-12-31","value":-25156000000,"profit":false},{"date":"2023-12-31","value":-37674400000,"profit":false}] |
Total Non-Operating Income/Expense | (55.41M) | (127.46M) | 1.59M | (16.34M) | 11.07M | [{"date":"2019-12-31","value":-500.64,"profit":false},{"date":"2020-12-31","value":-1151.61,"profit":false},{"date":"2021-12-31","value":14.41,"profit":true},{"date":"2022-12-31","value":-147.64,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (146.45M) | (188.79M) | (179.68M) | (278.17M) | (376.11M) | [{"date":"2019-12-31","value":-14644800000,"profit":false},{"date":"2020-12-31","value":-18879000000,"profit":false},{"date":"2021-12-31","value":-17968200000,"profit":false},{"date":"2022-12-31","value":-27816900000,"profit":false},{"date":"2023-12-31","value":-37611000000,"profit":false}] |
Income Taxes | (21.00K) | (19.36M) | 409.00K | 313.00K | 223.00K | [{"date":"2019-12-31","value":-5.13,"profit":false},{"date":"2020-12-31","value":-4733.25,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":76.53,"profit":true},{"date":"2023-12-31","value":54.52,"profit":true}] |
Income After Taxes | (146.43M) | (169.43M) | (180.09M) | (278.48M) | (376.33M) | [{"date":"2019-12-31","value":-14642700000,"profit":false},{"date":"2020-12-31","value":-16943100000,"profit":false},{"date":"2021-12-31","value":-18009100000,"profit":false},{"date":"2022-12-31","value":-27848200000,"profit":false},{"date":"2023-12-31","value":-37633300000,"profit":false}] |
Income From Continuous Operations | (146.43M) | (169.43M) | (180.09M) | (278.48M) | (376.33M) | [{"date":"2019-12-31","value":-14642700000,"profit":false},{"date":"2020-12-31","value":-16943100000,"profit":false},{"date":"2021-12-31","value":-18009100000,"profit":false},{"date":"2022-12-31","value":-27848200000,"profit":false},{"date":"2023-12-31","value":-37633300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (146.43M) | (169.43M) | (180.09M) | (278.48M) | (111.40M) | [{"date":"2019-12-31","value":-14642700000,"profit":false},{"date":"2020-12-31","value":-16943100000,"profit":false},{"date":"2021-12-31","value":-18009100000,"profit":false},{"date":"2022-12-31","value":-27848200000,"profit":false},{"date":"2023-12-31","value":-11139900000,"profit":false}] |
EPS (Diluted) | (2.98) | (1.48) | (3.03) | (4.37) | (4.75) | [{"date":"2019-12-31","value":-298,"profit":false},{"date":"2020-12-31","value":-148,"profit":false},{"date":"2021-12-31","value":-303,"profit":false},{"date":"2022-12-31","value":-437,"profit":false},{"date":"2023-12-31","value":-475,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
TVTX | |
---|---|
Cash Ratio | 1.46 |
Current Ratio | 1.71 |
Quick Ratio | 1.68 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
TVTX | |
---|---|
ROA (LTM) | -26.14% |
ROE (LTM) | -279.94% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
TVTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.06 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.06 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
TVTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 7.35 |
P/B | 76.10 |
Price/FCF | NM |
EV/R | 7.96 |
EV/Ebitda | NM |
Travere Therapeutics Inc (TVTX) share price today is $17.15
Yes, Indians can buy shares of Travere Therapeutics Inc (TVTX) on Vested. To buy Travere Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in TVTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Travere Therapeutics Inc (TVTX) via the Vested app. You can start investing in Travere Therapeutics Inc (TVTX) with a minimum investment of $1.
You can invest in shares of Travere Therapeutics Inc (TVTX) via Vested in three simple steps:
The 52-week high price of Travere Therapeutics Inc (TVTX) is $20.33. The 52-week low price of Travere Therapeutics Inc (TVTX) is $5.12.
The price-to-earnings (P/E) ratio of Travere Therapeutics Inc (TVTX) is
The price-to-book (P/B) ratio of Travere Therapeutics Inc (TVTX) is 76.10
The dividend yield of Travere Therapeutics Inc (TVTX) is 0.00%
The market capitalization of Travere Therapeutics Inc (TVTX) is $1.50B
The stock symbol (or ticker) of Travere Therapeutics Inc is TVTX